Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications

 Includes withdrawal syndromes from benzodiazepines, ketamine/esketamine, mood stabilizers.

Psychother Psychosom 2020;89:283–306.  "Studies on psychotropic medications decrease, discontinuation, or switch have uncovered withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class (i.e., benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers) according to the diagnostic criteria of Chouinard and Chouinard [Psychother Psychosom. 2015;84(2):63–71], which encompass new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders."

Popular posts from this blog

The Concept of Treatment-Refractory Addiction: A Call to the Field

Not all patients respond to effective and approved treatment interventions, and there has been growing recognition in the medical field of these “resistant” or refractory illnesses (eg, treatment-resistant depression, resistant hypertension). In the field of substance use disorders, there has not been an explicit acknowledgement of treatment-refractory addiction (TRA) despite substantial evidence that many patients do not respond to standard-of-care treatment interventions. This article provides a justification for TRA as a critically important condition to recognize and define. TRA is not conceptualized as a diagnosis, but as a signal that a current treatment approach has not worked. The article addresses areas in need of research and consensus in order to ensure the approach to TRA is uniform, thoughtfully addressed, and data-driven. By explicitly acknowledging TRA, clinicians, researchers, and patients and their families can begin to explore the unique features of this population an...
Read more

EXPANDING MAIL-BASED DISTRIBUTION OF DRUG-RELATED HARM REDUCTION SUPPLIES AMID COVID-19 AND BEYOND

Brian S. Barnett MD, Sarah E. Wakeman MD, Corey S. Davis JD, MSPH, Jamie Favaro MSW, and Josiah D. Rich MD, MPH Published Online: May 05, 2021 https://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2021.306228 WHAT IS  NEXT DISTRO ? An online and mail-based  harm reduction service  designed to reduce opioid overdose death, prevent injection-related disease transmission, and improve the lives of people who use drugs.
Read more